Abstract: Novel coronavirus pneumonia (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2（SARS-CoV-2） has spurred a global health crisis. To date, there is no effective therapy for COVID-19 patients. Convalescent plasma from recovered infection patient contains neutralizing antibodies against the same infection. Transfusion convalescent plasma to infected patients is a form of passive antibody therapy, can be traced back as early as the 20th century. The CP has been used in outbreaks of other respiratory infections. Available evidence from use of convalescent plasma in SARS-CoV-1 and MERS patients suggested that CP was safe. Blood establishment should develop COVID-19 CP workflow according to national and local guidelines, to illustrate the individual steps that need to be undertaken, including assessment of CP donor eligibility, informed consent, recruitment, pre-donation screening, antibody testing, collections, processing, virus testing, storage, distribution, transfusion of CP and assessment of efficacy, in order to maximize safety of CP donors and recipients. At the same time, we also need to pay attention to the potential risks of CP transfusion, including：antibody-mediated enhancement(ADE), allergic transfusion reactions, febrile reactions, transfusion-related acute lung injury (TRALI), transfusion-associated cardiac overload (TACO). In a complex nursing environment with a large number of confounding factors, Randomized Controlled Trial（RCT） is the most effective and efficient strategy to determine the efficacy and safety of COVID-19 CP clinical therapy.

Key words: Convalescent, plasma, Qualification, of, blood, donors, Apheresis, plasma, Antibody, detection, Potential, risks